A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The main purpose of • To evaluate the safety, tolerability and pharmacokinetic characteristics of SIBP-03(Recombinant anti-HER3 humanized monoclonal antibody injection). A secondary purpose * Assess the immunogenicity of SIBP-03. Exploratory purpose * Explore potential biomarkers; * Preliminary evaluation of the antitumor efficacy of SIBP-03.
Epistemonikos ID: 04b0bc684fc3fdb73dfa2ec5324d93a2c859fd31
First added on: May 10, 2024